Using angiotensin receptor blockers to help repair lung tissue in COPD patients
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
This study is looking at how a type of medication called angiotensin receptor blockers (ARBs) might help people with COPD and emphysema by reducing inflammation and helping heal their lungs, so if you're living with these conditions, this research could be for you!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10649490 on NIH RePORTER |
What this research studies
This research investigates the potential of angiotensin receptor blockers (ARBs) to not only reduce inflammation but also promote the repair of lung tissue in patients suffering from chronic obstructive pulmonary disease (COPD) and emphysema. The study builds on previous findings that ARBs can reverse damage in animal models and has shown promise in human trials, where patients experienced stabilization or improvement in their condition. By focusing on enhancing cell survival and matrix production in the lungs, this research aims to provide a dual therapeutic approach for COPD. Patients will be monitored for changes in lung function and tissue architecture over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with COPD or emphysema, particularly those who have not responded adequately to existing therapies.
Not a fit: Patients with mild or early-stage COPD who do not exhibit significant lung damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that not only alleviate symptoms of COPD but also promote actual healing of lung tissue.
How similar studies have performed: Previous studies have shown promising results with angiotensin receptor blockers in reversing emphysema in certain patient populations, indicating a potential for success in this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Neptune, Enid R — Johns Hopkins University
- Study coordinator: Neptune, Enid R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.